Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem
- PMID: 17015870
- DOI: 10.7326/0003-4819-145-7-200610030-00010
Narrative review: lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem
Abstract
Recent national recommendations have proposed that physicians should titrate lipid therapy to achieve low-density lipoprotein (LDL) cholesterol levels less than 1.81 mmol/L (<70 mg/dL) for patients at very high cardiovascular risk and less than 2.59 mmol/L (<100 mg/dL) for patients at high cardiovascular risk. To examine the clinical evidence for these recommendations, the authors sought to review all controlled trials, cohort studies, and case-control studies that examined the independent relationship between LDL cholesterol and major cardiovascular outcomes in patients with LDL cholesterol levels less than 3.36 mmol/L (<130 mg/dL). For those with LDL cholesterol levels less than 3.36 mmol/L (<130 mg/dL), the authors found no clinical trial subgroup analyses or valid cohort or case-control analyses suggesting that the degree to which LDL cholesterol responds to a statin independently predicts the degree of cardiovascular risk reduction. Published studies had avoidable limitations, such as a reliance on ecological (aggregate) analyses, use of analyses that ignore statins' other proposed mechanisms of action, and failure to account for known confounders (especially healthy volunteer effects). Clear, compelling evidence supports near-universal empirical statin therapy in patients at high cardiovascular risk (regardless of their natural LDL cholesterol values), but current clinical evidence does not demonstrate that titrating lipid therapy to achieve proposed low LDL cholesterol levels is beneficial or safe.
Comment in
-
Lack of evidence for recommended low-density lipoprotein cholesterol treatment targets.Ann Intern Med. 2007 Apr 17;146(8):614; author reply 614-5. doi: 10.7326/0003-4819-146-8-200704170-00019. Ann Intern Med. 2007. PMID: 17438325 No abstract available.
-
Lack of evidence for recommended low-density lipoprotein cholesterol treatment targets.Ann Intern Med. 2007 Apr 17;146(8):614; author reply 614-5. doi: 10.7326/0003-4819-146-8-200704170-00018. Ann Intern Med. 2007. PMID: 17438326 No abstract available.
Similar articles
-
Lack of evidence for recommended low-density lipoprotein cholesterol treatment targets.Ann Intern Med. 2007 Apr 17;146(8):614; author reply 614-5. doi: 10.7326/0003-4819-146-8-200704170-00018. Ann Intern Med. 2007. PMID: 17438326 No abstract available.
-
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.Drugs. 2004;64(11):1181-96. doi: 10.2165/00003495-200464110-00003. Drugs. 2004. PMID: 15161326 Review.
-
Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.Circulation. 2017 Nov 14;136(20):1878-1891. doi: 10.1161/CIRCULATIONAHA.117.027966. Epub 2017 Sep 6. Circulation. 2017. PMID: 28877913 Clinical Trial.
-
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review.
-
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).J Am Coll Cardiol. 2014 Feb 11;63(5):430-3. doi: 10.1016/j.jacc.2013.09.048. Epub 2013 Oct 23. J Am Coll Cardiol. 2014. PMID: 24161333 Clinical Trial.
Cited by
-
What we know and do not know about sex and cardiac disease.J Biomed Biotechnol. 2010;2010:562051. doi: 10.1155/2010/562051. Epub 2010 Apr 22. J Biomed Biotechnol. 2010. PMID: 20445744 Free PMC article. Review.
-
Correlation Between Atherosclerotic Cardiovascular Disease Risk Factors and Statin Prescribing Patterns.Am Health Drug Benefits. 2021 Dec;14(4):140-146. Am Health Drug Benefits. 2021. PMID: 35261718 Free PMC article.
-
Moneyball, gambling, and the new cholesterol guidelines.Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):311-4. doi: 10.1161/CIRCOUTCOMES.114.000876. Epub 2014 Mar 4. Circ Cardiovasc Qual Outcomes. 2014. PMID: 24594549 Free PMC article. No abstract available.
-
Non-cardiovascular effects associated with statins.BMJ. 2014 Jul 17;349:g3743. doi: 10.1136/bmj.g3743. BMJ. 2014. PMID: 25035309 Free PMC article. Review.
-
Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV.Indian J Endocrinol Metab. 2013 Jul;17(4):628-35. doi: 10.4103/2230-8210.113753. Indian J Endocrinol Metab. 2013. PMID: 23961478 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical